Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2014

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except per share amounts):

	Year Ended December 31,
	2014			2013			2012
EPS Numerator:
Net loss	$	(90,908	)	$	(89,027	)	$	(98,840	)


EPS Denominator—Basic:
Weighted-average common shares outstanding		87,662			87,288			74,967


EPS Denominator—Diluted:
Weighted-average common shares outstanding		87,662			87,288			74,967
Dilutive effect of stock options, shares under ESPP and warrant		—			—			—

Weighted-average shares outstanding and common stock equivalents		87,662			87,288			74,967


Net loss per common share:
Basic and diluted	$	(1.04	)	$	(1.02	)	$	(1.32	)

These securities consist of the following (in thousands except per share data):

	December 31,
	2014		2013		2012
Outstanding options		16,971		15,532		13,604
Warrant		200		200		200
Weighted average exercise price of options	$	9.07	$	10.55	$	11.52
Weighted average exercise price of warrant	$	6.61	$	6.61	$	6.61